Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Financing Activities (2017 - 2025)

Protagonist Therapeutics' Cash from Financing Activities history spans 9 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 29.62% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $22.9 million, down 11.56%, while the annual FY2025 figure was $22.9 million, 11.56% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.8 million at Protagonist Therapeutics, down from $5.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $125.4 million in Q2 2021 and bottomed at $527000.0 in Q4 2023.
  • The 5-year median for Cash from Financing Activities is $3.5 million (2024), against an average of $18.4 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 99.46% in 2022 before it soared 15807.65% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $2.2 million in 2021, then crashed by 74.55% to $553000.0 in 2022, then decreased by 4.7% to $527000.0 in 2023, then surged by 664.9% to $4.0 million in 2024, then dropped by 29.62% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Cash from Financing Activities are $2.8 million (Q4 2025), $5.7 million (Q3 2025), and $2.9 million (Q2 2025).